Experimental Animal Facility, ICMR-National JALMA Institute for Leprosy and Other Mycobacterial Diseases, M. Miyazaki Marg , Tajganj, Agra, Uttar Pradesh, India.
Microbiology and Molecular Biology Laboratory, Department of Biological Sciences, Indian Institute of Science Education and Research , Bhopal, India.
Microbiol Spectr. 2023 Dec 12;11(6):e0459722. doi: 10.1128/spectrum.04597-22. Epub 2023 Oct 6.
To combat the rapidly emerging drug-resistant , it is now essential to look for alternative therapeutics. Mycobacteriophages can be considered as efficient therapeutics due to their natural ability to infect and kill mycobacteria including . Here, we have exploited the mycolyl-arabinogalactan esterase property of LysB encoded from mycobacteriophage D29. This study is novel in terms of targeting a multi-drug-resistant pathogenic strain of with LysB and also examining the combination of anti-TB drugs and LysB. All the experiments include external administration of LysB. Therefore, the remarkable lytic activity of LysB overcomes the difficulty to enter the complex cell envelope of mycobacteria. Targeting the intracellularly located by LysB and non-toxicity to macrophages take the process of the development of LysB as a drug one step ahead, and also, the interaction studies with rifampicin and isoniazid will help to form a new treatment regimen against tuberculosis.
为了应对迅速出现的耐药性，现在必须寻找替代疗法。分枝杆菌噬菌体由于其天然的感染和杀死分枝杆菌（包括 ）的能力，可被视为有效的治疗方法。在这里，我们利用了分枝杆菌噬菌体 D29 编码的 LysB 的酰阿拉伯甘露聚糖酯酶特性。就用 LysB 靶向多药耐药的致病性 株以及检查抗结核药物和 LysB 的组合而言，这项研究具有新颖性。所有实验均包括 LysB 的外部给药。因此，LysB 对 的显著裂解活性克服了进入分枝杆菌复杂细胞包膜的困难。通过 LysB 靶向细胞内定位的 ，以及对巨噬细胞的无毒作用，将 LysB 的开发过程向前推进了一步，并且与利福平利福平和异烟肼的相互作用研究将有助于形成一种针对结核病的新治疗方案。
